Deal Details
Natera Completes $250.3 Million Follow-On Offering
Summary
Natera, Inc. (“Natera” or the “Company”) (NASDAQ: NTRA) recently completed a follow-on offering of 4,550,000 shares of its common stock at a price to the public of $55.00 per share, generating gross proceeds of approximately $250.3 million. Natera has granted the underwriters a 30-day option to purchase up to an additional 682,500 shares of its common stock at the public offering price. Natera intends to use the net proceeds from this offering for working capital and general corporate purposes and continued investments in research and development for its core technology.
Baird served as a lead manager on this offering.
About
Natera is a global leader in cell-free DNA testing, dedicated to oncology, women’s health and organ health. The Company aims to make personalized genetic testing and diagnostics part of the standard of care to protect health, and enable earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 150 peer-reviewed publications that demonstrated high accuracy. Natera, Inc. is headquartered in Austin, Texas.CONTACT US TO LEARN MORE
- Date
- September 2023
- Company
- Natera, Inc.
- Transaction
- Equity Capital Markets
- Sectors
- Healthcare
- Verticals
-
Life Sciences Tools & Diagnostics
- Target Geography
- North America
Share
